Improved Antitumour Immunity in Neuroblastoma with IL-2 and IL-12
Author Information
Author(s): Siapati K E, Barker S, Kinnon C, Michalski A, Anderson R, Brickell P, Thrasher A J, Hart S L
Primary Institution: Institute of Child Health, London, UK
Hypothesis
Can a combination of IL-2 and IL-12 enhance antitumour immunity in neuroblastoma?
Conclusion
The combination of IL-2 and IL-12 significantly improved antitumour effects in a murine model of neuroblastoma.
Supporting Evidence
- Transfected neuroblastoma cells produced high levels of IL-2 and IL-12.
- The combination of IL-2 and IL-12 was more effective in eradicating established tumors than either cytokine alone.
- Mice receiving IL-2 and IL-12 transfected cells remained tumor-free for at least 75 days.
- Significant antitumor protection was achieved with lower levels of IL-12 and IL-2.
- Vaccination with IL-2 and IL-12 transfected cells resulted in a 91% overall response rate.
Takeaway
Researchers found that using two special proteins, IL-2 and IL-12, together can help the body fight off a type of childhood cancer called neuroblastoma better than using either one alone.
Methodology
Neuroblastoma cell lines were transfected with IL-2 and IL-12 genes using a nonviral vector, and their effects were tested in vitro and in vivo using mouse models.
Limitations
The study primarily focused on local vaccine administration and may require further optimization for clinical use.
Participant Demographics
A/J mice were used for in vivo experiments.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website